Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)Gopa Iyer,Arlene O. Siefker‐Radtke,Matthew I. Milowsky,Neal D. Shore,Xin Gao,Melissa A. Reimers,Noah M. Hahn,Rasha Cosman,Nobuaki Matsubara,Andrea Necchi,Debbie G.J. Robbrecht,Armelle Vinceneux,Enrique Grande, Jae‐Lyun Lee,Tian Zhang,Tormod Kyrre Guren,Ulrich M. Lauer,Michal Sarfaty,Bernhard J. Eigl,Syed A. Hussain, Xiang Zhao,Arjun Vasant Balar,Kaitlyn Francese,Ryan C. Widau,Benjamin GarmezyCancer Research（2023）引用 0|浏览36暂无评分关键词advanced solid tumors,inhibitor,first-in-human,isoform-selectiveAI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
